The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
23
10
2019
accepted:
24
03
2020
pubmed:
10
4
2020
medline:
15
5
2021
entrez:
10
4
2020
Statut:
ppublish
Résumé
Methotrexate (MTX) is the first-line treatment for psoriasis in China. The metabolic processes of MTX include various proteins and genes. Previous studies have shown that gene polymorphisms had significant impacts on the efficacy of MTX. However, the influence of gene polymorphisms has not been reported in the Chinese psoriatic patients. The aim of this study was to verify the impacts of candidate genes polymorphisms on the effectiveness of MTX in a Chinese psoriatic population. In this study, we enrolled 259 psoriasis patients from two clinical centres. Each of them received MTX treatment at 7.5-15 mg/week for at least 8 weeks. Patients were stratified as responders and non-responders according to whether the Psoriasis Area and Severity Index score declined more than 75% (PASI75). According to previous reports, 16 single nucleotide polymorphisms (SNPs) were selected and genotyped for each patient using the Sequenom platform. Fisher's exact test, the chi-square test, Mann-Whitney tests and ANOVA analyses were used for statistical analysis. Among 259 patients, there were 182 males and 77 females, 63 patients with psoriatic arthritis and 196 patients without arthritis phenotype, and the age of all patients ranged from 19 to 70 years (49.7 ± 13.6). The baseline PASI value of patients was 13.8 ± 8.5, and 33.2% of patients achieved a PASI75 response after MTX treatment. Patients carrying the ATP-binding cassette subfamily B member 1 gene (ABCB1) rs1045642 TT genotype were associated with more severe psoriasis skin lesion (P = 0.032). Furthermore, the ABCB1 rs1045642 TT genotype was found to be more frequent in non-responders (P = 0.017), especially in moderate-to-severe patients (P = 0.002) and patients without psoriatic arthritis (P = 0.026) after MTX treatment. We have demonstrated for the first time that polymorphism of the ABCB1 rs1045642 TT genotype is predictive of a worse clinical response of skin lesions to MTX therapy in a Chinese psoriatic population.
Sections du résumé
BACKGROUND
BACKGROUND
Methotrexate (MTX) is the first-line treatment for psoriasis in China. The metabolic processes of MTX include various proteins and genes. Previous studies have shown that gene polymorphisms had significant impacts on the efficacy of MTX. However, the influence of gene polymorphisms has not been reported in the Chinese psoriatic patients.
OBJECTIVE
OBJECTIVE
The aim of this study was to verify the impacts of candidate genes polymorphisms on the effectiveness of MTX in a Chinese psoriatic population.
METHODS
METHODS
In this study, we enrolled 259 psoriasis patients from two clinical centres. Each of them received MTX treatment at 7.5-15 mg/week for at least 8 weeks. Patients were stratified as responders and non-responders according to whether the Psoriasis Area and Severity Index score declined more than 75% (PASI75). According to previous reports, 16 single nucleotide polymorphisms (SNPs) were selected and genotyped for each patient using the Sequenom platform. Fisher's exact test, the chi-square test, Mann-Whitney tests and ANOVA analyses were used for statistical analysis.
RESULTS
RESULTS
Among 259 patients, there were 182 males and 77 females, 63 patients with psoriatic arthritis and 196 patients without arthritis phenotype, and the age of all patients ranged from 19 to 70 years (49.7 ± 13.6). The baseline PASI value of patients was 13.8 ± 8.5, and 33.2% of patients achieved a PASI75 response after MTX treatment. Patients carrying the ATP-binding cassette subfamily B member 1 gene (ABCB1) rs1045642 TT genotype were associated with more severe psoriasis skin lesion (P = 0.032). Furthermore, the ABCB1 rs1045642 TT genotype was found to be more frequent in non-responders (P = 0.017), especially in moderate-to-severe patients (P = 0.002) and patients without psoriatic arthritis (P = 0.026) after MTX treatment.
CONCLUSION
CONCLUSIONS
We have demonstrated for the first time that polymorphism of the ABCB1 rs1045642 TT genotype is predictive of a worse clinical response of skin lesions to MTX therapy in a Chinese psoriatic population.
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2059-2065Subventions
Organisme : Central South University
ID : 2016GL03
Organisme : National Natural Science Foundation of China
ID : 81573049
Organisme : National Natural Science Foundation of China
ID : 81773329
Organisme : National Natural Science Foundation of China
ID : 81803118
Organisme : National Natural Science Foundation of China
ID : 81830096
Organisme : National Natural Science Foundation of China
ID : 81974479
Organisme : Science and Technology Innovation Foundation of Dalian, China
ID : 2019J13SN93
Organisme : Management Research Foundation of Xiangya Hospital
Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol 2011; 65: 870-873.
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168: 1303-1310.
Ding X, Wang T, Shen Y et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 2012; 22: 663-667.
Boehncke WH Schon MP. Psoriasis. Lancet 2015; 386: 983-994.
van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277-292.
Liu P, Kuang Y, Zhang J et al. Effect of acitretin and methotrexate on treatment of severe plaque psoriasis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016; 41: 804-808.
Gyulai R, Bagot M, Griffiths CE et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol 2015; 29: 224-231.
Zhao S, Chen C, Liu S et al. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci 2013; 70: 182-189.
Ranganathan P. ABC transporter genes and methotrexate response in rheumatoid arthritis. J Rheumatol 2013; 40: 536.
Qiu Q, Huang J, Lin Y et al. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96: e6337.
Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011; 12: 1449-1463.
Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1366-1377.
Chen Y, Zou K, Sun J, Yang Y, Liu G. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics 2017; 18: 175-195.
Chen Y, Shen Z. Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL. Tumour Biol 2015; 36: 4913-4921.
Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925-1929.
Hayashi H, Tazoe Y, Tsuboi S et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2013; 28: 164-168.
Ghodke-Puranik Y, Puranik AS, Shintre P et al. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics 2015; 16: 2019-2034.
Committee on Psoriasis CSoD. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition). Chin J Dermatol 2019; 52: 667-710.
Yu Q, Tong Y, Cui L et al. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. Int Immunopharmacol 2019; 73: 442-450.
Henseler T Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
Nast A, Boehncke WH, Mrowietz U et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10(Suppl 2): S1-95.
Ayoib A, Hashim U, Gopinath SCB, Md AMK. DNA extraction on bio-chip: history and preeminence over conventional and solid-phase extraction methods. Appl Microbiol Biotechnol 2017; 101: 8077-8088.
Kuang YH, Lu Y, Yan KX et al. Genetic polymorphism predicting Methotrexate efficacy in Chinese patients with psoriasis vulgaris. J Dermatol Sci 2019; 93: 8-13.
Lajevardi V, Hallaji Z, Daklan S et al. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 2015; 54: 95-101.
Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
Flytstrom I, Stenberg B, Svensson A Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121.
Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Update 2006; 9: 227-246.
Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478.
Kato T, Hamada A, Mori S, Saito H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2012; 27: 192-199.
Kameda H, Amano K, Sekiguchi N et al. Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod Rheumatol 2004; 14: 442-446.
Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 546-554.
He X, Sun M, Liang S, Li M, Li L, Yang Y. Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis. Pharmacogenomics 2019; 20: 381-392.
Dusseaux M, Martin E, Serriari N et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117: 1250-1259.
Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 2009; 34: 355-361.
Res PC, Piskin G, de Boer OJ et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5: e14108.
Teunissen MBM, Yeremenko NG, Baeten DLP et al. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 2014; 134: 2898-2907.
Ogdie A, Langan S, Love T et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford) 2013; 52: 568-575.
Li R, Sun J, Ren LM et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 2012; 51: 721-729.
Yang Q, Qu L, Tian H et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol 2011; 25: 1409-1414.
Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasilia. An Bras Dermatol 2012; 87: 539-544.
Ogdie A Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 545-568.
Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017; 76: 377-390.
Yamamoto T Kawada A. Clinical characteristics of Japanese patients with psoriatic arthritis: Comparison with East Asian countries. J Dermatol 2018; 45: 273-278.
Yamamoto T, Ohtsuki M, Sano S et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol 2016; 43: 1193-1196.
Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 183-190.
Chen W, Zhang X, Zhang W, Peng C, Zhu W, Chen X. Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients. Sci Rep 2018; 8: 13182.
Zhou X, He Y, Kuang Y et al. Whole exome sequencing in psoriasis patients contributes to studies of acitretin treatment difference. Int J Mol Sci 2017; 18: 295.
Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 2007; 7: 404-407.
Hashiguchi M, Shimizu M, Hakamata J et al. Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population. J Pharm Health Care Sci 2016; 2: 35.
Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54: 1087-1095.
Haagsma CJ, Blom HJ, van Riel PL et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79-84.
Lima A, Monteiro J, Bernardes M et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int 2014; 2014: 368681.
van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007; 8: 141-150.
Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol 2017; 73: 965-971.
Nefic H, Mackic-Djurovic M, Eminovic I. The frequency of the 677C>T and 1298A>C polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) gene in the population. Med Arch 2018; 72: 164-169.
Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol 2015; 64: 313-323.
Vallelunga A, Pegoraro V, Pilleri M et al. The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease. Neurol Sci 2014; 35: 73-77.
El-Hadidy MA, Abdeen HM, Abd E-ASM, Al-Harrass M. MTHFR gene polymorphism and age of onset of schizophrenia and bipolar disorder. Biomed Res Int 2014; 2014: 318483.
Kilic S, Ozdemir O, Silan F et al. Possible association between germline methylenetetrahydrofolate reductase gene polymorphisms and psoriasis risk in a Turkish population. Clin Exp Dermatol 2017; 42: 8-13.